The Big (& Small) Picture of Nonalcoholic Steatohepatitis
Building Your Understanding to Combat a Growing Problem
Clinical Practice Guidelines
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
Chalasani N, et al. Hepatology. 2018;67(1):328-357.
Clinical Resources
Histological Scoring System for Nonalcoholic Fatty Liver Disease.
Transplant Pathology Internet Services, 2009.
NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.
MD+CALC online calculator, 2016.
Patient Resources
American College of Gastroenterology (ACG) Patient Education and Resource Center.
The ACG website. provides a basic overview of NAFLD and includes patient-centered podcasts.
American Liver Foundation.
The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.
The NIDDK website for NAFLD and nonalcoholic steatohepatitis (NASH) provides comprehensive patient-centered information and resources, including an overview of clinical trial participation.
Suggested Readings
Non-alcoholic fatty liver disease: an expanded review.
Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.
Nonalcoholic fatty liver disease.
Brunt EM, et al. Nat Rev Dis Primers. 2015;1:15080.
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Buzzetti E, et al. Metabolism. 2016;65(8):1038-1048.
The natural course of non-alcoholic fatty liver disease.
Calzadilla Bertot L, Adams LA. Int J Mol Sci. 2016;17(5):E774.
Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.
Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, et al. Hepatology. 2017;67(5):1754-1767.
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).
Golabi P, et al. Medicine (Baltimore). 2018;97(13):e0214.
Pharmacotherapy for NASH: current and emerging.
Konerman MA, Jones JC, Harrison SA. J Hepatol. 2018;68(2):362-375.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.
Loomba R, et al. Hepatology. 2018;67(2):549-559.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.
The therapeutic landscape of non-alcoholic steatohepatitis.
Perazzo H, Dufour JF. Liver Int. 2017;37(5):634-647.
Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.
Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study.
Ratziu V, et al. J Hepatol. 2018;68(suppl 1):S1-S2.
Nonalcoholic fatty liver disease: a systematic review.
Rinella ME. JAMA. 2015;313(22):2263-2273.
Management of NAFLD: a stage-based approach.
Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.
Treatment of NAFLD with diet, physical activity and exercise.
Romero-Gómez M, et al. J Hepatol. 2017;67(4):829-846.
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, et al. N Engl J Med. 2010;362(18):1675-1685.
Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.
Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
Wong VW, et al. Hepatology. 2010;51(2):454-462.
Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, et al. Hepatology. 2016;64(1):73-84.
Building Your Understanding to Combat a Growing Problem
Relevant Resources
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Informing the Future of NASH Diagnosis and Assessment
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management
A Multidisciplinary Approach
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
